Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma - Takeaways - MDSpire

Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma

  • By

  • Martin Zarba

  • Eddy Saad

  • Karl Semaan

  • Talal El Zarif

  • Evan Ferrier

  • Connor Wells

  • Razane El Hajj Chehade

  • Naveen S. Basappa

  • Hedyeh Ebrahimi

  • Mahrukh Huseni

  • Romain Banchereau

  • Rana R. McKay

  • Lori Wood

  • Benoit Beuselinck

  • Cristina Suárez

  • Kosuke Takemura

  • Aly-Khan A. Lalani

  • Haoran Li

  • Lavinia Anne Spain

  • Arnoud J. Templeton

  • Thomas B. Powles

  • Georg A. Bjarnason

  • Guillermo de Velasco

  • Toni K. Choueiri

  • Daniel Y. C. Heng

  • April 15, 2026

  • 0 min

Share

  • 1

    The IMDC prognostic model classifies mRCC patients into favorable, intermediate, and poor risk groups based on six clinical factors.

  • 2

    Combination therapies, including IO-IO and IO-VE, have expanded treatment options for mRCC, but their benefit in favorable risk patients is debated.

  • 3

    A very favorable risk subgroup within the favorable category shows significantly better median overall survival compared to the standard favorable group.

  • 4

    This study utilized retrospective data to validate the prognostic implications of the IMDC model and its subgroups in contemporary mRCC treatment.

  • 5

    Genomic and transcriptomic analyses were conducted to explore the underlying characteristics of the very favorable risk group in mRCC.

Original Source(s)

Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma

  • by Martin Zarba, Eddy Saad, Karl Semaan, Talal El Zarif, Evan Ferrier, Connor Wells, Razane El Hajj Chehade, Naveen S. Basappa, Hedyeh Ebrahimi, Mahrukh Huseni, Romain Banchereau, Rana R. McKay, Lori Wood, Benoit Beuselinck, Cristina Suárez, Kosuke Takemura, Aly-Khan A. Lalani, Haoran Li, Lavinia Anne Spain, Arnoud J. Templeton, Thomas B. Powles, Georg A. Bjarnason, Guillermo de Velasco, Toni K. Choueiri, Daniel Y. C. Heng

  • April 15, 2026

Related Content

Combination Immunotherapy Approaches in Metastatic Renal Cell Carcinoma with Favorable Risk Scores: A Meta-Analysis of Individual Patient Data

Assessment of the effectiveness and safety of anti-VEGF/VEGFR monotherapy versus its combination with immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma: a network meta-analysis

Molecular Profiling, Prognostic Insights, and Immune Landscape Evaluation of NUDT16 in Clear Cell Renal Cell Carcinoma